TEEC CHEE Signs Exclusive Agency Agreement in India, Unveiling a New Chapter of Globalization Strategy

Recently, TEEC CHEE officially announced the signing of a three-year exclusive strategic cooperation agreement with Density Pharmachem Private Ltd., a renowned pharmaceutical agent in India. Under the agreement, Density Pharmachem will obtain the exclusive agency rights for TEEC CHEE's full range of biological reagents in the Indian market, including core products such as basal media and serum-free media. This milestone marks TEEC CHEE's formal entry into India—the "Pharmacy of the World"—and represents a crucial step forward in its global layout.

As a key growth engine of the global biopharmaceutical industry, the Indian pharmaceutical market is experiencing a golden period of development. Data shows that the Indian pharmaceutical market size reached USD 42 billion in 2024 and is projected to exceed USD 65 billion by 2030, with a compound annual growth rate (CAGR) of 8%. Its biotechnology industry grows at an annual rate of 15%, and the cleanroom market scale surpasses USD 1 billion, driving a sustained surge in demand for high-quality biological reagents. Particularly in the serum-free media sector, fueled by the rapid development of cell therapy, vaccine R&D, and other cutting-edge fields, the global market size is expected to reach USD 3.14 billion by 2031 with a CAGR of 11.4%. As the supplier of 20% of the world's generic drugs, India faces a significant gap in related products. TEEC CHEE's entry into the Indian market at this juncture precisely targets the enormous market opportunities brought by the upgrading of the local biopharmaceutical industry.

With years of deep cultivation in the biological reagents sector, TEEC CHEE has built a comprehensive product system through core technological breakthroughs. Its serum-free media products feature precisely formulated amino acids, vitamins, growth factors, and other components, achieving clear chemical composition and strong batch stability. These products effectively avoid the contamination risks associated with traditional serum-containing media, comply with international regulatory standards such as FDA and EMA, and are widely applicable in advanced fields including biopharmaceutical production, vaccine R&D, and gene therapy. On the other side of the cooperation, Density Pharmachem, as a leading local pharmaceutical agent in India, boasts a nationwide sales network and profound industry resources. It has established long-term partnerships with top Indian pharmaceutical enterprises such as Sun Pharmaceutical and Dr. Reddy's Laboratories, possessing mature channel operation capabilities and market insights in the biological reagents distribution sector. Through the in-depth integration of technological advantages and local channel resources, the two parties will provide cost-effective biological reagent solutions for the Indian market.

"The Indian market serves as a vital fulcrum for TEEC CHEE's globalization strategy," stated the Global Marketing Director of TEEC CHEE. "We are honored to cooperate with Density Pharmachem. Leveraging its local operation experience and channel advantages, combined with TEEC CHEE's technological accumulation in the serum-free media field, we are confident in quickly penetrating the Indian market, delivering more competitive products and services to local biopharmaceutical enterprises, and supporting the high-quality development of India's pharmaceutical industry."

The CEO of Density Pharmachem also expressed great optimism about the cooperation prospects: "TEEC CHEE's serum-free media products excel in stability and safety, perfectly aligning with the Indian market's demand for high-quality biological reagents. We will fully leverage our channel advantages to promote the wide application of the products in scenarios such as pharmaceutical companies, research institutions, and CDMOs, achieving win-win results for both parties."

The successful penetration of the Indian market has laid a solid foundation for TEEC CHEE's globalization strategy. It is revealed that TEEC CHEE will take the Indian market as a starting point to further expand into emerging markets including Southeast Asia, the Middle East, and Russia. The biopharmaceutical industries in these regions are accelerating their rise: the Southeast Asian IVD market is expected to exceed USD 1.63 billion by 2030, Russia's medical device market has an import dependency rate as high as 78%, and the Middle East has emerged as a new blue ocean for biological reagents driven by continuous medical investment. TEEC CHEE will gradually build a global marketing network and service system by seeking high-quality local partners and establishing regional service centers, enabling Chinese-manufactured biological reagent products to benefit more countries and regions.

Looking ahead, TEEC CHEE will continue to increase R&D investment, focusing on technological innovation and iteration of core products such as serum-free media. Meanwhile, adhering to an open and cooperative attitude, it will join hands with global partners to contribute Chinese strength to promoting the innovative development of the global biopharmaceutical industry.